Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.3, and our video podcast, CANCER BUZZ TV.

Industry News Archive

Texas Medicaid Designates Pegfilgrastim-cbqv on the Preferred Drug List

For 2021, Texas Medicaid has designated pegfilgrastim-cbqv (Udenyca®, Coherus Biosciences) the preferred pegfilgrastim on the Preferred Drug List (PDL). Udenyca® coverage details are available here.

Please contact marketaccess@coherus.com for additional information.

Posted 3/15/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us